Related Experiment Video

Updated: Jul 1, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.3K

Hypomethylating agents for elderly patients with acute myeloid leukemia: a PRISMA systematic review and meta-analysis

R-J Zhang1, J-H Zhai, Z-J Zhang

  • 1Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China. 13593169668@163.com.

European Review for Medical and Pharmacological Sciences
|April 8, 2021
PubMed
Abstract

Insights

Hypomethylating agents (HMAs) improve overall survival and complete remission rates in elderly acute myeloid leukemia (AML) patients compared to conventional care. While HMAs increase risks of neutropenia, thrombocytopenia, and pneumonia, they remain well-tolerated and effective AML treatments.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Abnormal DNA methylation is a key factor in acute myeloid leukemia (AML) development.
  • Hypomethylating agents (HMAs) like decitabine and azacitidine are established AML therapies.

Purpose of the Study:

  • To evaluate the therapeutic advantages of HMAs versus conventional care regimens (CCR) or placebo in elderly AML patients.
  • To compare efficacy and safety profiles of HMAs against CCR or placebo.

Main Methods:

  • Systematic literature search of PubMed, Embase, and Cochrane Central Register of Controlled Trials up to July 15, 2020.
  • Inclusion of seven randomized controlled trials with 1966 participants.
  • Meta-analysis using RevMan 5.3 to calculate hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI).

Main Results:

  • HMAs demonstrated improved overall survival compared to CCR (HR=0.76, 95% CI [0.69-0.85], p<0.01).
  • Complete remission rates were higher with HMAs than CCR (RR=1.46, 95% CI [1.08-1.99], p=0.01).
  • Increased incidence of neutropenia (RR=1.30), thrombocytopenia (RR=1.14), and pneumonia (RR=1.37) observed with HMAs versus CCR.

Conclusions:

  • Despite higher risks of neutropenia, thrombocytopenia, and pneumonia, HMAs are well-tolerated and effective for elderly AML patients.
  • HMAs offer significant therapeutic benefits in terms of survival and remission rates for this patient population.

More Related Videos

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.8K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.4K

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...